Welcome to our dedicated page for VASO CORPORATION news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on VASO CORPORATION stock.
Vaso Corporation reports developments for a diversified medical technology business spanning network and IT services, professional sales services for medical equipment, and proprietary medical products. Company updates commonly cover operating results by segment, deferred revenue trends, gross profit, expenses, and the effect of portfolio changes such as the sale of its healthcare IT business unit.
Recurring news also includes subsidiary activity. VasoHealthcare represents GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments, while VasoMedical manages proprietary medical equipment and software and overseas assets, including China-based subsidiaries. Other updates address material agreements, shareholder meeting matters, and governance developments.
Vaso Corporation (OTCQX: VASO) reported stronger results for the quarter ended June 30, 2026, reflecting its shift toward core healthcare operations. Revenue from continuing operations rose 8.3% year over year to $11.2 million, driven by a 20.0% increase in professional sales services and a 31.0% rise in equipment segment revenue, partially offset by lower IT revenue following the November 2025 healthcare IT divestiture.
Gross profit increased 11.9% to $8.9 million, while SG&A expenses were nearly flat at $7.7 million. Operating income climbed to $974 thousand from $93 thousand, and net income from continuing operations grew to $840 thousand from $323 thousand. Adjusted EBITDA from continuing operations improved to $1.1 million, up from $145 thousand a year earlier.
Vaso classified its NetWolves network service business as discontinued operations in Q2 and completed its sale on July 31, 2026, finalizing its exit from network and IT services. Total deferred revenue reached $41.5 million, up 8.9% from June 30, 2025. For the first half of 2026, operating cash flow was $4.8 million, and cash and cash equivalents totaled approximately $52.3 million as of August 7, 2026. At June 30, 2026, current assets were $55.2 million, current liabilities $32.9 million, and stockholders’ equity $29.2 million.
Vaso Corporation (OTCQX: VASO) announced it completed the sale of its managed network services and connectivity business, NetWolves Network Services LLC, to COEO Solutions on July 31, 2026, through an equity sale.
The transaction, priced at $14.5 million in cash subject to customary post-closing adjustments tied to net working capital, cash, indebtedness, seller expenses and escrows, supports Vaso’s strategic focus on its healthcare operations via VasoHealthcare and VasoMedical. Together with the November 2025 sale of VasoHealthcare IT, this deal completes the divestiture of Vaso’s IT segment under VasoTechnology. Vaso plans to support an orderly transition for NetWolves stakeholders, while COEO, a managed network and cloud communications provider, assumes ownership to drive NetWolves’ next phase of growth.
Vaso Corporation (OTCQX: VASO) has appointed Shaun McMeans to its Board of Directors, effective July 23, 2026. McMeans is currently CFO of Nabsys and previously served as CFO of HTG Molecular Diagnostics, bringing extensive finance, accounting and operational leadership experience across life sciences and technology sectors.
Vaso (OTCQX: VASO) reported Q1 2026 revenue of $19.4 million, down 0.5% year over year, but up 4.8% excluding a divested healthcare IT service business. Gross profit rose 1.9% to $11.6 million, while net loss narrowed to $887 thousand from $1.1 million.
Operating loss was $1.3 million and Adjusted EBITDA was negative $1.1 million. Operating cash outflow increased to $12.6 million, largely due to payment timing. Deferred revenue grew 11.6% to $39.5 million, and cash and equivalents were about $38.5 million on May 8, 2026.
Vaso Corporation (OTCQX: VASO) reported fiscal 2025 revenue of $89.1 million, up 2.7% year-over-year, and gross profit of $54.7 million (up 5%). Net income rose to $1.6 million and cash plus short-term investments reached $35.1 million as of December 31, 2025.
The company sold its healthcare IT business in November 2025, recorded a goodwill impairment, generated $9.3 million of operating cash flow, and saw deferred revenue increase to $38.6 million.
Vaso Corporation (OTCQX: VASO) announced that its subsidiary VasoHealthcare signed an amendment extending its sales representation agreement with GE HealthCare (NASDAQ: GEHC) through December 31, 2030. This marks the fifth extension of a partnership that began in May 2010, which will span over 20 years under the latest term.
Under the amendment, VasoHealthcare will continue representing GE HealthCare’s diagnostic imaging and ultrasound portfolio, including CT, MR, molecular imaging, X-ray, mammography, interventional solutions, plus related service and financial offerings, aiming to ensure continuity in sales representation and customer support nationwide.
Vaso Corporation (OTCQX: VASO) announced on November 19, 2025 that it reached an agreement, subject to conditions, to sell its subsidiary VasoHealthcare IT Corp. to Nano-X Imaging (Nasdaq: NNOX).
The buyer will pay up to $800,000 in total consideration: $200,000 at closing and up to $600,000 as an earnout tied to post-closing performance. VasoHealthcare IT represented less than 5% of Vaso’s total revenue. The parties intend to complete the sale within a couple of weeks. Vaso said it expects to use proceeds to invest in other business lines and strategic initiatives.
Vaso (OTCQX: VASO) reported third-quarter 2025 results for the three months ended September 30, 2025, with total revenue of $22.7 million, up 9.1% year‑over‑year. Gross profit rose to $13.9 million, an increase of 18.2%, and the company recorded net income of $1.7 million versus a net loss of $1.2 million in Q3 2024, a $2.9 million improvement. Adjusted EBITDA was $1.6 million versus negative $1.2 million a year earlier. Cash and cash equivalents were $34.9 million at quarter end, and operating cash flow for the first nine months of 2025 was $9.0 million versus $3.6 million in the prior-year period.
All three business segments contributed to revenue growth; professional sales services led with an 18.7% increase. SG&A rose modestly while deferred and subscription revenues continued to trend upward.
Vaso Corporation (OTCQX: VASO), a MedTech company, reported its Q2 2025 financial results with revenue of $20.0 million, slightly down 1.3% from $20.2 million in Q2 2024. The company posted a net loss of $197,000 compared to a net income of $1.2 million in the same period last year.
The company's professional sales service segment experienced a 4.0% decline, while the IT segment saw a 0.9% increase. Notable metrics include record-high deferred revenue of $38.1 million (up from $31.7 million YoY), gross profit of $11.8 million (down 2.9%), and strong cash position of $32.6 million. Operating cash flow for Q2 2025 was $6.8 million, demonstrating robust cash generation despite operational challenges.
The professional sales service segment saw a 7.1% revenue increase, while the IT segment grew by 1.6%. The equipment segment experienced a slight decline of 3.6%. Total deferred revenue reached $35.4 million, up 12.7% year-over-year, providing revenue stability and financial visibility.
The company maintained a strong balance sheet with $25.3 million in cash as of March 31, 2025, which improved to approximately $30.5 million by May 9, 2025. Despite increased market uncertainties, management remains cautiously optimistic about 2025, citing historically stronger performance in later quarters.